Navigation Links
Exiqon Announces 2009 North American Grant Award Winners
Date:7/1/2009

Exiqon A/S (NASDAQ OMX Copenhagen: "EXQ") today announced the two winners of their 2009 North American Grant Program. Exiqon had recently announced the development of a new research grant program, open to researchers from academic and non-profit institutions across North America, engaged in microRNA research.

(PRWEB) July 1, 2009 -- Exiqon A/S (NASDAQ OMX Copenhagen: "EXQ") today announced the two winners of their 2009 North American Grant Program. Exiqon had recently announced the development of a new research grant program, open to researchers from academic and non-profit institutions across North America, engaged in microRNA research.

The 2009 Grant Program winners are: Dr. Liang Zhang, Ph.D., of the Rockefeller University Fuchs Laboratory of Mammalian Cell Biology and Development, and Dr. Toshifumi Sugatani, Ph.D., of the Hruska Laboratory in the Department of Pediatric Research at the Washington University in St. Louis School of Medicine.

Dr. Sugatani will receive funding to pursue research aimed at elucidating the role of microRNAs (miRNAs) in physiological and pathophysiological bone remodeling in vivo. This research has potential therapeutic indications for the treatment of osteoporosis, a disease which currently affects more than 75 million individuals worldwide.

Dr. Zhang will receive funding to pursue research aimed at determining how microRNAs (miRNAs) regulate the maintenance and development of epidermal stem cell populations. This research has implications for a wide range of disorders and conditions, including skin cancer. Skin cancer is the most prevalent form of cancer, with over 1 million new diagnoses each year in the United States alone.

To qualify for the grant awards, Dr. Zhang and Dr. Sugatani each submitted abstracts providing background on their field of study, specific aims of the project, as well as detailed experimental plans, including how each would implement research tools from Exiqon. The two winners were faced with strong competition. Submission statistics for the grant program, divulged by Exiqon, revealed a significant response from the research community at large, including nearly 200 informational requests, and more than 90 qualified applications received as of June 15th, the program's deadline.

"The level of response we have received to this program has, quite frankly, exceeded our initial expectations," said Chris Harbert, Director of Marketing, Exiqon North American Life Sciences. "The range of pathologies indicated in the pool of applications clearly illustrates the importance of microRNA investigation in current biomedical research, and reaffirms the strong need for available tools and funding opportunities in this field. We are very proud to help support Dr. Zhang and Dr. Sugatani seek new breakthroughs in microRNA research. It will be exciting to see what unfolds."

The two award winners will split the grant program seed funding of $25,000. Both grant finalists may use Exiqon Grant Program awards for the purchase of any Exiqon microRNA product or service. Exiqon offers a complete product line for microRNA investigation, including products for RNA isolation, Microarray analysis, qRT-PCR analysis, Northern Blotting, In Situ Hybridization, and Knockdown studies. Exiqon also offers microRNA profiling services for both microarray and qRT-PCR analysis, complete with full sample QC and customized data analysis and reporting.

Additional information:
Additional information is available through Exiqon representatives located across North America. Interested parties are invited to contact Exiqon at 1-888-647-2879.

Information is also available from these web pages:

Fuchs Laboratory of Mammalian Cell Biology & Development
http://www.rockefeller.edu/labheads/fuchs/intro.php

Hruska Laboratory of Pediatric Research
http://research.peds.wustl.edu/labs/hruska_keith_a/Home/tabid/545/Default.aspx

Exiqon
www.exiqon.com/ls

About Exiqon:
Exiqon is dedicated to making the discovery, development, and application of medicines better, safer and more cost-effective by way of research and diagnostic tests that can identify the treatment needs of specific patient populations.

Exiqon provides research and diagnostic products and services for the analysis of microRNA molecules in a wide variety of disease models and pathologies. Our goal is to help enable groundbreaking discoveries in academic, biotech and pharmaceutical organizations worldwide, who work at the forefront of modern medicine.

Exiqon has more than 200 employees and is listed on the NASDAQ OMX in Copenhagen and categorized as a biotech company (Small Cap+).

Exiqon is financed until expected breakeven in 2011.

###

Read the full story at http://www.prweb.com/releases/Exiqon/microRNA_research/prweb2593964.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved  

Related medicine news :

1. Exiqon Announces New Grant Program for MicroRNA Research
2. The Meetings Industry...Stirred But Not Shaken by Current Economic Setbacks - Patriot Meetings Announces Their 360 Degree Program that Ensures Successful Meetings
3. Medco Announces Date for Second-Quarter 2009 Financial Results
4. Roche Diabetes Care Announces Unique Coaching Program for Diabetes Educators as Part of Long-Term Commitment to Fight the Disease
5. Anixter Center Announces Leadership Changes
6. Availity Announces Strategic Relationship With Anthem Blue Cross and Blue Shield in Kentucky
7. AIUM announces management agreement with the International Society of Therapeutic Ultrasound
8. JAG Media Holdings, Inc. Announces a Further Update of the Status of Its Acquisition of CardioGenics Inc.
9. Amira Pharmaceuticals Announces Initial Positive Phase 1 Clinical Data for AM211, a Novel Product Candidate for the Treatment of Respiratory Diseases
10. Connectyx Technologies Holdings Groups CEO Gives Shareholders a Summary of Events for First Half of 2009 and Announces Teleconference Call on July 9th to Discuss Future Strategy
11. YoCream Announces the First Soft Serve Frozen Yogurt With Beneficial Probiotics Clinically Proven to Strengthen the Digestive System.
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Exiqon Announces 2009 North American Grant Award Winners 
(Date:2/22/2017)... (PRWEB) , ... February 22, 2017 , ... The SeniorCare ... the 2017 Forecast —on Thursday, February 23, 2017, at 1:00 PM ET. A recording ... is part of the Interactive Webinar Series. , If you want to find out ...
(Date:2/22/2017)... ... 22, 2017 , ... Social media marketing is transitioning from a singular person ... & Jones’ delves into this insight and more in its latest episode of its ... Vener meets up with social media strategist and partner of the digital firm Med|Ed ...
(Date:2/22/2017)... ... 22, 2017 , ... In today’s world, homeowners face a ... market, it is easy to start feeling frustrated and confused. To help Dallas ... security consultation. , Home Security Hardware Choices, There are innumerable choices for home ...
(Date:2/22/2017)... ... February 22, 2017 , ... Apptricity® Corporation, a leading global ... management, today announced that Keppel Corporation has selected Apptricity Travel and Expense Management ... “We are excited to announce the partnership between Keppel and Apptricity for our ...
(Date:2/21/2017)... ... February 21, 2017 , ... Robins & ... in Durant, Oklahoma, on Feb. 21. , The celebration began with a ribbon ... clinic employees, the construction team and tribal leadership. , Choctaw Nation Durant ...
Breaking Medicine News(10 mins):
(Date:2/22/2017)... 22, 2017 Oncternal Therapeutics, Inc., a ... rare and common malignancies, today announced the closing ... company intends to use the proceeds to further ... to advance preclinical development of a new ROR1-targeted ... a first-in-class anti-ROR1 monoclonal antibody being developed to ...
(Date:2/22/2017)...  CVS Pharmacy is the first national retail pharmacy ... (PHO), the primary source of artificial trans fats in ... products. The retailer now offers over 600 exclusive snack ... fats. This comes a year and a half ahead of ... for processed foods to be reformulated without artificial trans ...
(Date:2/22/2017)... 2017 Des scanners sur smartphone destinés aux professionnels ... Europe , au Moyen-Orient et en Afrique  ... Clarius Mobile Health , une société de santé ... au Canada , a annoncé aujourd,hui qu,elle a reçu ... fil Clarius C3 et L7, destinés à être utilisés par des professionnels ...
Breaking Medicine Technology: